Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
Objective To estimate the association between the use of sodium glucose co-transporter-2 (SGLT2) inhibitors and postmarket harms as identified by drug regulatory agencies.Design We conducted a systematic review and meta-analysis of randomised controlled trials (RCT). Six large databases were searche...
Saved in:
| Main Authors: | Kris Aubrey-Bassler, John-Michael Gamble, Jennifer R Donnan, Catherine A Grandy, Eugene Chibrikov, Carlo A Marra, Karissa Johnston, Michelle Swab, Jenna Hache, Daniel Curnew, Hai Nguyen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2019-02-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/9/1/e022577.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Sodium-glucose transporter-2 (SGLT2; SLC5A2) enhances cellular uptake of aminoglycosides.
by: Meiyan Jiang, et al.
Published: (2014-01-01) -
ALDH2 mediates the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on improving cardiac remodeling
by: Han Liu, et al.
Published: (2024-10-01) -
Effect of sodium glucose cotransporter-2 inhibitors (SGLT-2is) on the clinical outcomes of patients with diabetic atrial fibrillation
by: Selim Aydemir, et al.
Published: (2024-12-01) -
Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near
by: Gilda M. Portalatin, et al.
Published: (2025-01-01) -
Adipokines and Adipose Tissue: The Role and Use of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors in Patients with Diabetes or Heart Failure
by: Michalina Mazurkiewicz, et al.
Published: (2025-04-01)